Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Bioheart, Inc. (BHRT)

Add BHRT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Gaintrader, HybridTrader, BioheartInc
Search This Board:
Last Post: 10/20/2014 4:30:30 PM - Followers: 149 - Board type: Free - Posts Today: 0


Bioheart, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 


MyoCell SDF-1 



Bioheart’s lead product candidate is MyoCell®, a muscle stem cell therapy that is intended to improve cardiac function months or even years after a patient has suffered severe heart damage due to a heart attack.

MyoCell SDF-1 has received approval from the FDA to begin human clinical trials and is intended to be an improvement to MyoCell.

The MyoCath is a disposable needle injection catheter used for the delivery of biologic solutions to a targeted treatment site within the myocardium, the inner wall of the heart. 

Adipose (fat) tissue is readily available and has been shown to be rich in microvascular, myogenic and angiogenic cells.  Bioheart has recently applied to the FDA to begin trials using adipose derived stem cells or AdipoCell™ in patients with chronic ischemic cardiomyopathy.  


The Bioheart Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease.We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.




Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.

**Important: Mike Tomás' personal StemCellCEO blog!**

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame


Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Charles A. Hart  53 Director
Sam Ahn  59 Director
Kristen Comella  37 Director, Chief Scientific Officer
Sheldon T. Anderson 63 Director

Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 
BHRT - Daily Candlesticks


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
BHRT News: Amended Statement of Ownership (sc 13g/a) 10/15/2014 09:32:37 AM
BHRT News: Current Report Filing (8-k) 10/10/2014 04:00:53 PM
BHRT News: Amended Statement of Changes in Beneficial Ownership (4/a) 08/14/2014 01:01:15 PM
BHRT News: Amended Statement of Changes in Beneficial Ownership (4/a) 08/14/2014 12:58:49 PM
BHRT News: Statement of Changes in Beneficial Ownership (4) 08/13/2014 11:38:10 AM
#10184  Sticky Note Small Cap Voice Interview with BioHeart HybridTrader 06/25/14 06:27:59 PM
#6744  Sticky Note Bioheart Announces Positive 6 Month Data From Angel Gaintrader 04/03/14 05:59:37 PM
#11393   Flat lined out today, big vol drop off- Hopalongstocks 10/20/14 04:30:30 PM
#11392   Holding up just fine here. All stocks re-trace, BrownRickRoss 10/20/14 01:02:12 PM
#11390   A "twitter" link to an old article from Hopalongstocks 10/20/14 10:30:33 AM
#11389   Interesting.... HybridTrader 10/20/14 08:41:18 AM
#11388   BioHeart posted this link on its Twitter page andyshow 10/20/14 03:11:40 AM
#11387   $50-$100? Way too low! I want more! GLTA BrownRickRoss 10/19/14 08:03:47 PM
#11385   "$50-$100"?? An increase in price of about 2,500 Hopalongstocks 10/19/14 07:45:15 PM
#11384   This is the PERFECT place to be adding. Pierrocks 10/19/14 07:19:48 PM
#11383   Saw some buying and holding Friday, stranger things Chunky Salsa 10/19/14 06:17:53 PM
#11382   Next supposed level is $50-$100 in my opinion. Gsdubb 10/19/14 05:44:01 PM
#11381   .0131-.0132 next level of support Chunky Salsa 10/19/14 04:01:11 PM
#11380   Read the 10-K and 10-Q filings (it takes Hopalongstocks 10/17/14 10:16:26 PM
#11379   You got me.... NOT!! IMO. BIOHEART RELEASES Q2 andyshow 10/17/14 08:36:33 PM
#11377   "How do you not see the massive potential Hopalongstocks 10/17/14 04:07:15 PM
#11376   How do you not see the massive potential andyshow 10/17/14 03:53:22 PM
#11375   "They mentioned they recently opened up a new Hopalongstocks 10/17/14 03:49:22 PM
#11374   Thanks Gs. They mentioned they recently opened up andyshow 10/17/14 03:43:03 PM
#11373 Gsdubb 10/17/14 03:16:32 PM
#11372 Gsdubb 10/17/14 03:16:12 PM
#11371   Can you post the link Gs please? andyshow 10/17/14 03:14:14 PM
#11370   New corporate restructure videos out now! Haven't watched Gsdubb 10/17/14 02:52:01 PM
#11369   The science is rock solid that's not the Chunky Salsa 10/17/14 01:56:53 PM
#11368   Low volume shakeout scare tactics that no one BrownRickRoss 10/17/14 01:20:20 PM
#11367   Autocorrect? Lol Gsdubb 10/17/14 01:16:03 PM
#11366   "How in The halibut is this going to Hopalongstocks 10/17/14 01:01:19 PM
#11365   Lol halibut. Sorry. Investaholic33 10/17/14 12:49:15 PM
#11364   How in The halibut is this going to cjlopez 10/17/14 12:44:29 PM
#11363   Notice: FINRA has halted trading in OTC equity Nano1 10/17/14 11:44:01 AM
#11362   What are your thoughts on the science? Gsdubb 10/17/14 11:40:17 AM
#11361   "Be careful I think this can go below Hopalongstocks 10/17/14 11:13:28 AM
#11360   "Bioheart on the breakout board!" Hopalongstocks 10/17/14 11:01:45 AM
#11359   Be careful I think this can go below Chunky Salsa 10/17/14 10:51:21 AM
#11358   Bioheart on the breakout board! It's been a Gsdubb 10/17/14 08:32:35 AM
#11357   October 15, 2014 08:00 ET locksflooring 10/17/14 06:48:41 AM
#11356   Added today:) Thanks for the cheaps$$$ Pierrocks 10/16/14 07:09:34 PM
#11355   NEWS OUT! BIOHEART PARTNERS WITH STEMLAB! locksflooring 10/16/14 06:08:44 PM
#11354 Gsdubb 10/16/14 04:54:54 PM
#11353   thats 5%..10% different ball game BigAlBalbosci 10/16/14 04:50:00 PM
#11352   I think if you own under 10% the HybridTrader 10/16/14 04:24:43 PM
#11351   Tiny buy on close- to "walk it back Hopalongstocks 10/16/14 04:22:14 PM
#11350   .0155 holy cow- looks like volume just spiked Hopalongstocks 10/16/14 04:12:04 PM
#11349   Form 13 filing is showing Northstar has gained Hopalongstocks 10/16/14 04:08:46 PM
#11348   i think you are correct…. that alarmed me…. BigAlBalbosci 10/16/14 03:54:20 PM
#11347   where does the $$$ come from for the trials? BigAlBalbosci 10/16/14 03:40:46 PM
#11346   "I am assuming that since it has been Hopalongstocks 10/16/14 03:40:01 PM
#11345   It says if the owner ceases to own, Gsdubb 10/16/14 03:35:27 PM
#11344   I am assuming that since it has been Gsdubb 10/16/14 03:29:40 PM
#11343   that was for a check box I accidentally BigAlBalbosci 10/16/14 03:24:49 PM
#11342   "That's from all of the money put into Hopalongstocks 10/16/14 03:24:36 PM
#11341   This is just a reporting document of what Gsdubb 10/16/14 03:22:45 PM